Guanidine Hydrazone (2a): A Novel Disease-Modifying Treatment for Parkinson's Disease

被引：0
|
作者：
Persico, Michele [1 ]
Fang, Tracy Shi Zhang [1 ]
Eleuteri, Simona Carmen [1 ]
Simon, David Keith [1 ]
机构：
[1] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA USA
来源：
ANNALS OF NEUROLOGY | 2023年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
S221
引用
收藏
页码：S174 / S174
页数：1
相关论文
共 50 条
  • [1] Disease-modifying treatment in Parkinson's disease - opportunities and obstacles
    Bandmann, O.
    FEBS OPEN BIO, 2019, 9 : 40 - 40
  • [2] Disease-Modifying Drugs in Parkinson’s Disease
    Ariane Park
    Mark Stacy
    Drugs, 2015, 75 : 2065 - 2071
  • [3] Disease-modifying drugs and Parkinson's disease
    Allain, Herve
    Bentue-Ferrer, Daniele
    Akwa, Yvette
    PROGRESS IN NEUROBIOLOGY, 2008, 84 (01) : 25 - 39
  • [4] Disease-Modifying Drugs in Parkinson's Disease
    Park, Ariane
    Stacy, Mark
    DRUGS, 2015, 75 (18) : 2065 - 2071
  • [5] Disease-Modifying Strategies for Parkinson's Disease
    Kalia, Lorraine V.
    Kalia, Suneil K.
    Lang, Anthony E.
    MOVEMENT DISORDERS, 2015, 30 (11) : 1442 - 1450
  • [6] Novel disease-modifying therapeutics for the treatment of Alzheimer's disease
    Leger, Gabriel C.
    Massoud, Fadi
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2013, 6 (04) : 423 - 442
  • [7] Multitarget disease-modifying therapy in Parkinson's disease?
    Calabresi, Paolo
    Di Filippo, Massimiliano
    LANCET NEUROLOGY, 2015, 14 (10): : 975 - 976
  • [8] Promising disease-modifying therapies for Parkinson's disease
    Dawson, Valina L.
    Dawson, Ted M.
    SCIENCE TRANSLATIONAL MEDICINE, 2019, 11 (520)
  • [9] PRESENTATION: IRX4204 as a Novel Disease-Modifying compound for Treatment of Parkinson's Disease.
    Pasinetti, G. M.
    Wang, J.
    Bilski, A.
    MOVEMENT DISORDERS, 2013, 28 (10) : E2 - E2
  • [10] Emerging disease-modifying strategies targeting α-synuclein for the treatment of Parkinson's disease
    O'Hara, Darren M.
    Kalia, Suneil K.
    Kalia, Lorraine V.
    BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (15) : 3080 - 3089
12345